Vericel Corp VCEL Stock Forecast
AI-powered price prediction and analysis for Vericel Corp · Alpha · vs marketSwitch to Total
See VCEL's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Vericel Corp
Vericel Corp (VCEL) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry.
Where VCEL sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| VCEL Vericel Corp | $2.65B | 105.7x | |
| AMGN Amgen Inc | $248.84B | 26.7x | |
| GILD Gilead Sciences, Inc. | $207.84B | – | |
| MRNA Moderna, Inc. | $96.40B | – | |
| ARGX Argenx Se | $55.37B | 23.5x | |
| RVMD Revolution Medicines, Inc. | $38.08B | – | |
| BIIB Biogen Inc. | $36.06B | 105.1x | |
| BNTX Biontech Se | $21.71B | 2.2x | |
| EXEL Exelixis, Inc. | $16.77B | 24.7x | |
| NBIX Neurocrine Biosciences Inc | $16.24B | 23.4x | |
| HALO Halozyme Therapeutics, Inc. | $13.96B | 24.9x | |
| TECH Bio-Techne Corp | $11.41B | 62.6x | |
| QGEN Qiagen N.V. | $11.03B | 36.1x | |
| KYMR Kymera Therapeutics, Inc. | $10.94B | – | |
| RGEN Repligen Corp | $10.77B | – | |
| PCVX Vaxcyte, Inc. | $9.21B | – | |
| KRYS Krystal Biotech, Inc. | $8.90B | 40.8x | |
| IBRX Immunitybio, Inc. | $8.49B | – | |
| TWST Twist Bioscience Corp | $7.56B | – | |
| IMVT Immunovant, Inc. | $5.86B | – | |
| CGON Cg Oncology, Inc. | $5.74B | – | |
| KOD Kodiak Sciences Inc. | $5.72B | – | |
| SRRK Scholar Rock Holding Corp | $5.54B | – | |
| CRSP Crispr Therapeutics Ag | $4.70B | – | |
| ADPT Adaptive Biotechnologies Corp | $4.28B | – | |
| RLAY Relay Therapeutics, Inc. | $3.73B | – | |
| IOVA Iovance Biotherapeutics, Inc. | $3.51B | – | |
| TARS Tarsus Pharmaceuticals, Inc. | $3.33B | – | |
| DNLI Denali Therapeutics Inc. | $3.15B | – | |
| ADMA Adma Biologics, Inc. | $2.96B | 19.7x | |
| BEAM Beam Therapeutics Inc. | $2.67B | 369.6x | |
| RXRX Recursion Pharmaceuticals, Inc. | $2.18B | – | |
| COAG Hemab Therapeutics Holdings, Inc. | $2.13B | – | |
| LIFE Atyr Pharma Inc | $2.08B | – | |
| BCRX Biocryst Pharmaceuticals Inc | $1.95B | – | |
| REPL Replimune Group, Inc. | $1.90B | – | |
| VIR Vir Biotechnology, Inc. | $1.86B | – | |
| MAZE Maze Therapeutics, Inc. | $1.81B | – | |
| MESO Mesoblast Ltd | $1.81B | – | |
| ALVO Alvotech | $1.62B | – | |
| NVAX Novavax Inc | $1.61B | 108.7x | |
| IMCR Immunocore Holdings Plc | $1.46B | – | |
| TSHA Taysha Gene Therapies, Inc. | $1.33B | – | |
| VOR Vor Biopharma Inc. | $1.15B | – | |
| CGEM Cullinan Therapeutics, Inc. | $1.01B | – | |
| ODTX Odyssey Therapeutics, Inc. | $907M | – | |
| GLUE Monte Rosa Therapeutics, Inc. | $874M | – | |
| IMTX Immatics N.V. | $829M | – | |
| MGTX Meiragtx Holdings Plc | $817M | 11.1x | |
| PRME Prime Medicine, Inc. | $807M | – | |
| SANA Sana Biotechnology, Inc. | $700M | – | |
| SLBT Sl Science Holding Ltd | $679M | – | |
| DNA Ginkgo Bioworks Holdings, Inc. | $671M | – | |
| SLDB Solid Biosciences Inc. | $663M | – | |
| AURA Aura Biosciences, Inc. | $657M | – | |
| FDMT 4d Molecular Therapeutics, Inc. | $621M | – | |
| DBVT Dbv Technologies S.A. | $616M | – | |
| CADL Candel Therapeutics, Inc. | $615M | – | |
| VALN Valneva Se | $551M | – | |
| ENTX Entera Bio Ltd. | $518M | 9.1x |
FAQ
Is Vericel Corp a good stock to buy?
Our AI analyzes Vericel Corp daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Vericel Corp predictions?
For VCEL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 49.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 24.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Vericel Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Vericel Corp? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.